The Quantellect read.As of Nov 19, 2026, 14 active firms cover Climb Bio Inc: 14 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $18.00 to $35.00, a moderate spread. The average target of $26.00 sits 180% above the current $9.30. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.23 next quarter toward $-0.99 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 active firms
Buy
Strong Buy17%
Buy1393%
Neutral00%
Sell00%
Strong Sell00%
Based on 14 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$26.00
+179.6% upside
Average target across 13 active firms as of Nov 19, 2026 vs $9.30 current
Highest Target$35.00
Average Target$26.00
Lowest Target$18.00
Detailed analyst forecasts for CLYM
Showing 1–13 of 13 named analysts shown · 14 active firms in the rating projection
As of Nov 19, 2026, 14 of 14 active firms rate CLYM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CLYM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.28 – $-0.20 · 5 analysts · +13% YoY
Next period, 5 analysts expect Climb Bio Inc to earn $-0.23 a share (range $-0.28 – $-0.20), versus $-0.20 a year earlier. Full-year consensus is $-0.75, growing to $-0.99 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $500.0K next year.
Top analysts covering Climb Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLYM.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$30.00+222.6% to target
Overall win rate
49%
+ Follow
#2
Laura Chico
Wedbush · Rank #55
Buy
$20.00+115.1% to target
Overall win rate
46%
+ Follow
#3
Yatin Suneja
Guggenheim · Rank #84
Buy
$35.00+276.3% to target
Overall win rate
50%
+ Follow
#4
Geulah Livshits
Chardan Capital · Rank #104
Buy
$22.00+136.6% to target
Overall win rate
43%
+ Follow
#5
Julian Harrison
BTIG · Rank #183
Buy
$32.00+244.1% to target
Overall win rate
41%
+ Follow
CLYM stock forecast FAQ
What is CLYM's average 12-month price target?+
The 13 active firms with a live target average $26.00 for Climb Bio Inc over the next 12 months, ranging from a $35.00 high to a $18.00 low, as of Nov 19, 2026.
Is CLYM stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 14 active firms as of Nov 19, 2026, 14 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CLYM?+
The Street-high target is $35.00 (Guggenheim), and the Street-low is $18.00 (Mizuho). The average of all 13 active-firm targets is $26.00.
How many active Wall Street firms cover CLYM?+
14 active firms have a recognized rating on Climb Bio Inc as of Nov 19, 2026, and 13 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CLYM?+
Among analysts who currently cover CLYM, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $30.00 target.
What is Climb Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.28 – $-0.20) across 5 analysts. Full-year EPS is projected at $-0.75, rising to $-0.99 the following year.
How much revenue is Climb Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $500.0K next year.
Have analysts been upgrading or downgrading CLYM lately?+
As of Nov 19, 2026, 14 of 14 active firms rate CLYM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLYM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.